Novo Nordisk axes 2 more obesity drugs as leading drugs 'raise the bar'; Diving deeper into R&D, CSL adds support for biotech incubator
Novo Nordisk is once again whittling away at its pipeline of obesity drugs.
In it latest quarterly update the pharma company noted:
In June 2020 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
